|Cancer Stem Cell News 8.07 February 27, 2019|
Investigators interrogated functionally-validated datasets of leukemia stem cell-specific genes together with their known protein interactors and selected 64 candidates for a competitive in vivo gain-of-function screen to identify genes that enhanced stemness in human cord blood hematopoietic stem and progenitor cells. [Blood]
Scientists demonstrated that radiation-induced senescent glioblastoma cells exhibited a senescence-associated secretory phenotype that functioned through NFκB signaling to influence changes in the tumor microenvironment, such as recruitment of Ly6G+ inflammatory cells and vessel formation. [Cell Death Differ]
The authors aimed to identify key signaling pathways specific for anaplastic thyroid carcinoma (ATC)-CSCs. The siRNA library targeting 719 kinases was used in a sphere formation assay and cell survival assay using ATC cell lines to select target molecules specific for the CSC properties. [Thyroid]
Researchers showed that the IL-6/STAT3 inflammatory signaling axis induced the deacetylation of FRA1 at the Lys-116 residue located within its DNA-binding domain. The HDAC6 deacetylase underlies this key modification leading to the increase of FRA1 transcriptional activity, the subsequent transactivation of NANOG expression, and the acquisition of stem-like cellular features. [Oncogene]
The authors found that prolonged transforming growth factor-β (TGF-β) exposure, mimicking the state of in vivo carcinomas, promoted stable epithelial-to-mesenchymal transition (EMT) in mammary epithelial and carcinoma cells, in contrast to the reversible EMT induced by a shorter exposure. [Sci Signal]
PD-L1 expression was positively correlated with the expression of stemness markers, and overexpression of PD-L1 contributed to chemoresistance and stemness-like properties in breast cancer cells via activating PI3K/Akt and ERK1/2 pathways. [EBioMedicine]
Scientists showed for the first time that BCL-3 acted as a co-activator of β-catenin/TCF-mediated transcriptional activity in colorectal cancer cells and that this interaction was important for Wnt-regulated intestinal stem cell gene expression. [Dis Model Mech]
Investigators found that a commercially available culture medium for maintenance of ES cells and induced pluripotent stem cells, mTeSR1, effectively prevented spontaneous differentiation by CD13+CD166‐ cells to CD13‐CD166+ cells and therefore maintained the CSC population in Li‐7 cell cultures. [Cancer Sci]
The levels of miR-451 were tested in colon cancer cell lines. Multiple functional and immunological assays were performed to analyze miR-451 induced growth changes in vitro and downstream effects on target proteins. [Gene]
The authors first summarize the current understanding of the regulation of self‐renewal by Krüppel‐like factor (KLF) proteins in embryonic stem cells through a KLF circuitry and then delve into the potential function of KLF4 in normal hematopoietic stem cells and its emerging role in leukemia‐initiating cells from pediatric patients with T‐cell acute lymphoblastic leukemia via repression of the mitogen‐activated protein kinase 7 pathway. [Stem Cells Transl Med]
Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.
The Centre for the Commercialization of Antibodies and Biologics (CCAB) announced a license agreement with Empirica Therapeutics Inc. aimed at developing new treatments for one of the deadliest forms of brain cancer, glioblastoma. [Centre for the Commercialization of Antibodies and Biologics]
Agios Announces FDA Acceptance of Supplemental New Drug Application for TIBSOVO® (Ivosidenib) for the Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation Not Eligible for Standard Therapy
Agios Pharmaceuticals, Inc. announced that the FDA has accepted the company’s supplemental New Drug Application for TIBSOVO® for the treatment of patients with newly diagnosed acute myeloid leukemia with an isocitrate dehydrogenase 1 (IDH1) mutation who are not eligible for standard therapy. [Agios Pharmaceuticals, Inc.]
Publishers of highly selective scholarly journals — including Nature and Science — say that they cannot comply with Plan S, a European-led initiative that mandates free access to research results on publication from 2020, unless its rules are changed. [Nature News]
President Donald Trump’s proposal in his State of the Union address to spend $500 million over 10 years on pediatric cancer research will begin in 2020 with a focus on sharing patients’ data, federal officials say. That plan is getting a mixed response from researchers and patient advocates, who also worry that the initiative will come at expense of other parts of the National Cancer Institute’s budget. [ScienceInsider]
NEW Gordon Research Conference: Mammary Gland Biology
Visit our events page to see a complete list of events in the community.
Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!
Comments or suggestions? Submit your feedback here.